Does Rallies show Form 4 insider transactions for LONA?

Yes. Rallies tracks LONA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LONA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LONA. It does not provide personalized investment advice.

LONA (LeonaBio, Inc. Common Stock) Stock Analysis - Insider Trades

LeonaBio, Inc. Common Stock (LONA) is a publicly traded the market company. As of May 21, 2026, LONA trades at $11.53 with a market cap of $95.16M and a P/E ratio of 0.00. LONA moved -6.54% today. Year to date, LONA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.21 to $14.21. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces LONA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LONA stock inside the company?

Recent LONA insider activity includes Litton Mark James sold 5.16K, Renninger Robert sold 906, Worthington Mark sold 1.33K, CHURCH KEVIN sold 1.36K, and San Martin Javier sold 1.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LONA Key Metrics

Key financial metrics for LONA
Metric	Value
Price	$11.53
Market Cap	$95.16M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$14.21
52-Week Low	$4.21
Volume	1
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent LONA Insider Trades

Litton Mark James sold 5.16K (~$27.69K) on Mar 4, 2026.
Renninger Robert sold 906 (~$4.87K) on Mar 4, 2026.
Worthington Mark sold 1.33K (~$7.13K) on Mar 4, 2026.
CHURCH KEVIN sold 1.36K (~$7.30K) on Mar 4, 2026.
San Martin Javier sold 1.72K (~$9.24K) on Mar 4, 2026.

Latest LONA News

LeonaBio Appoints Callori, Holles and Silverman to Strengthen Clinical Pipeline Strategy — May 7, 2026
LeonaBio to Complete ELAINE-3 Enrollment in Q4, Hosts April 29 Lasofoxifene Webinar — Apr 23, 2026
Lasofoxifene Demonstrates Bone Protection and Tumor Regression in ESR1-Mutant Preclinical Study — Apr 21, 2026
LeonaBio Raises $90M, Secures Phase 3 Lasofoxifene Rights with $146M Upside — Mar 26, 2026

LONA Analyst Consensus

2 analysts cover LONA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.

Common questions about LONA

Who is trading LONA stock inside the company?: Recent LONA insider activity includes Litton Mark James sold 5.16K, Renninger Robert sold 906, Worthington Mark sold 1.33K, CHURCH KEVIN sold 1.36K, and San Martin Javier sold 1.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LONA?: Yes. Rallies tracks LONA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LONA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LONA. It does not provide personalized investment advice.